-+ 0.00%
-+ 0.00%
-+ 0.00%

Is Pharma Mar (BME:PHM) Still A Bargain After Its 85% Run?

Simply Wall St·11/17/2026 00:23:08
Listen to the news

Pharma Mar has delivered a strong 84.7% gain over the past three years, yet the current share price of €66.60 puts a sharper spotlight on what investors are really paying for its earnings. With shorter term returns weaker this year, the question is whether that longer run still lines up with what the business is generating at the bottom line.

  • The 84.7% return over three years raises the stakes for anyone asking if Pharma Mar's earnings power has kept pace with the share price.
  • Recent share price softness may point investors back to the basics, such as how durable the company's profit profile and cash generation look against the risks in drug development.
  • The analysts covering Pharma Mar have run their own numbers. See what analysts think Pharma Mar's shares could be worth.

The stock's next move may depend on whether Pharma Mar's current earnings are strong enough to justify where the price now sits.

If you are weighing Pharma Mar's recent 3 year gain against its current earnings, it can help to compare it with 211 high quality undervalued stocks.

Is Pharma Mar a Bargain on Earnings?

A P/E ratio works well for Pharma Mar because earnings are a key focus for investors in profitable biotechs. On this metric, the stock trades on a P/E of 16.9x, which is below the broader biotech industry average of about 23.9x and also under the peer group average of roughly 22.9x. That puts the current share price at a lower multiple of earnings than many similar companies in the sector.

The model driven fair multiple for Pharma Mar, which factors in its own growth profile, profitability and risk, sits higher than where the shares trade today. That gap points to a valuation that screens as undervalued on this earnings yardstick, while still leaving you to judge how sustainable those profits look across a full drug cycle. Explore the numbers behind Pharma Mar's P/E valuation.

BME:PHM P/E Ratio as at Nov 2026
BME:PHM P/E Ratio as at Nov 2026

The Pharma Mar Narrative: What Would Justify Today's Price?

Pharma Mar's valuation story now hinges on what has to be true about the future path of its earnings, and that is where Simply Wall St Narratives step in. These scenarios spell out the kind of growth, margin profile and risk balance that would need to unfold for the share price to look materially higher or lower than today. Each one connects its number to a specific view on how Pharma Mar's prospects might shift, giving you something concrete to revisit as fresh information emerges.

One of the top narratives on Pharma Mar: 47% undervalued

This is the bullish analyst Narrative on Simply Wall St, built on the most optimistic analyst price target and forecasts, not one person's view.

"The numbers investors are paying for today imply a share price that does not fully reflect the potential impact of first-line Zepzelca approvals, Yondelis durability and the opportunity to in-license late-stage European oncology assets..."

Discover why this Narrative puts Pharma Mar at 47% undervalued.

One more angle on Pharma Mar that could change the story

Shareholders have picked over Pharma Mar's valuation, but the people steering the business and the way their incentives line up with your interests can be just as important to understand. See who runs Pharma Mar and how they are paid.